Boston Scientific Co. (BSX) Shares Bought by Parkwood LLC

Parkwood LLC grew its position in shares of Boston Scientific Co. (NYSE:BSX) by 1.8% in the 1st quarter, Holdings Channel reports. The fund owned 153,573 shares of the medical equipment provider’s stock after acquiring an additional 2,718 shares during the period. Boston Scientific comprises about 1.2% of Parkwood LLC’s holdings, making the stock its 28th largest position. Parkwood LLC’s holdings in Boston Scientific were worth $5,894,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. We Are One Seven LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $27,000. Athena Capital Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $28,000. Ipswich Investment Management Co. Inc. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $28,000. Essex Savings Bank acquired a new stake in shares of Boston Scientific in the first quarter valued at about $31,000. Finally, CWM LLC grew its stake in shares of Boston Scientific by 54.3% in the fourth quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 359 shares in the last quarter. Institutional investors own 91.61% of the company’s stock.

Shares of NYSE BSX opened at $36.37 on Tuesday. Boston Scientific Co. has a fifty-two week low of $29.42 and a fifty-two week high of $41.00. The company has a quick ratio of 1.12, a current ratio of 1.39 and a debt-to-equity ratio of 0.82. The company has a market cap of $50.87 billion, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 2.19 and a beta of 0.83.



Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). Boston Scientific had a net margin of 18.08% and a return on equity of 24.65%. The business had revenue of $2.49 billion for the quarter, compared to analyst estimates of $2.54 billion. During the same quarter last year, the business earned $0.33 EPS. Boston Scientific’s revenue for the quarter was up 4.8% compared to the same quarter last year. Equities analysts expect that Boston Scientific Co. will post 1.55 earnings per share for the current fiscal year.

In other Boston Scientific news, CFO Daniel J. Brennan sold 64,223 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $40.84, for a total transaction of $2,622,867.32. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Kevin J. Ballinger sold 20,900 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $40.74, for a total value of $851,466.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 298,116 shares of company stock worth $11,926,744. 0.66% of the stock is currently owned by company insiders.

A number of equities research analysts have recently issued reports on the company. Evercore ISI upgraded Boston Scientific from an “in-line” rating to an “outperform” rating and set a $36.20 target price for the company in a research note on Monday. BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research note on Thursday, April 25th. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price on shares of Boston Scientific in a research note on Wednesday, February 6th. Canaccord Genuity lowered their target price on Boston Scientific from $45.00 to $43.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Finally, SunTrust Banks restated a “buy” rating and set a $47.00 price objective on shares of Boston Scientific in a research note on Friday, February 8th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $41.53.

TRADEMARK VIOLATION WARNING: “Boston Scientific Co. (BSX) Shares Bought by Parkwood LLC” was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://dakotafinancialnews.com/2019/05/14/boston-scientific-co-bsx-shares-bought-by-parkwood-llc.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: The role of implied volatility with call option volume

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.